Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Systemic Immunosuppressant — Bullous Diseases / Autoimmune Dermatoses

Mycophenolate Mofetil

Brand names: CellCept, Myfenax

Mycophenolate mofetil is an immunosuppressant used after transplantation and as a steroid-sparing agent in various autoimmune and inflammatory conditions.

Dosing — not shown for this use

The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.

The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Mycophenolate Mofetil.

Clinical monograph

How it works

It inhibits inosine monophosphate dehydrogenase, selectively suppressing T- and B-lymphocyte proliferation.

Prescribing in practice

  • It is highly teratogenic and causes miscarriage — strict pregnancy prevention is required for anyone able to become pregnant, with relevant advice for men too (MHRA).
  • Bone-marrow suppression and increased infection risk (including reactivation and, rarely, PML) occur; gastrointestinal effects are common.
  • Avoid live vaccines; absorption is reduced by some antacids and by sevelamer.

Monitoring

Monitor full blood count regularly (especially early), review for infection, and confirm pregnancy-prevention measures.

Counselling the patient

  • Use effective contraception and avoid pregnancy — it can seriously harm a baby.
  • Report sore throat, fever, bruising or other signs of infection.
  • Take it consistently and attend monitoring blood tests.

Evidence & guidelines

Used after transplantation and as a steroid-sparing immunosuppressant, with strict pregnancy-prevention requirements (MHRA).

Reference: EMA Pregnancy Prevention Programme; BAD Pemphigus Guidelines; BAD Bullous Pemphigoid Guidelines 2012 (updated); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways